Genetic Study of Familial Factors in Patients With Colon Cancer
Familial Factors in the Development of Colon Cancer
RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer.
PURPOSE: Clinical trial to study the cancer-related genes in patients who have colon cancer or adenomatous polyps.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
- Identify human colon neoplasia susceptibility genes in patients with colon cancer or adenomatous polyps.
- Correlate the inheritance of novel susceptibility alleles for adenomatous polyposis of the colon with colon neoplasia in these patients.
- Correlate colon neoplasia susceptibility with the presence of COX-2, sPLA2, and DNMT genes in these patients.
- Identify a novel gene that governs increased susceptibility to colon adenoma and cancer in the genome of these patients.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Goldsboro, North Carolina, Forente stater, 27534
- Wayne Memorial Hospital, Incorporated
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
DISEASE CHARACTERISTICS:
- Diagnosis of colon cancer or polyps at age 70 or under
- Has a living full sibling with diagnosis of colon cancer or polyps at age 70 or under
- No history of familial adenomatous polyposis syndrome
- No hereditary nonpolyposis colon cancer, according to Amsterdam criteria
- No known I1370K adenomatous polyposis of the colon susceptibility variant
Enrolled on 1 of the following clinical trials:
- CLB-9581
- CLB-89803
- CLB-80001 NOTE: Patients do not need to be receiving protocol therapy. Patients who are outside the treatment protocol's follow-up range are eligible. Patients who discontinued therapy for any reason, including toxic effects, are eligible.
PATIENT CHARACTERISTICS:
Age
- 70 and under at diagnosis
Other
- No significant psychiatric illness that would preclude giving informed consent
- No inflammatory bowel disease (in patient or sibling)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Group 1
Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute. Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment. |
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Monica M. Bertagnolli, MD, Dana-Farber/Brigham and Women's Cancer Center
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CALGB-150008
- CDR0000271314 (Registeridentifikator: NCI Physician Data Query)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .